β³ Fetching live dividend data...
Home βΊ Calculator βΊ ENZB Dividend Calculator 2026
Enzo Biochem, Inc. Β· OTC
Price: $0.70 Β· Annual div: $0.10/share Β· Frequency: quarterly Β· Payout ratio: 50% Β· Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ENZB β $62868.33M in 10 years Β· $5,203,514,133.05/month
Enzo Biochem, Inc. operates as an integrated entity encompassing diagnostics, clinical laboratory services, and life sciences. The company is dedicated to developing, manufacturing, and commercializing diagnostic and research products, fundamentally rooted in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division focuses on creating, producing, and distributing essential products and tools for clients engaged in clinical research, pharmaceutical development, and broader bioscience investigations. Its extensive portfolio comprises proteins, antibodies, peptides, small molecules, labeling probes, dyes, and various kits. These offerings empower life science researchers in areas such as target identification and validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also serves scientific experts researching a wide array of health issues, including cancer, cardiovascular disorders, neurological diseases, diabetes and obesity, endocrine imbalances, infectious and autoimmune conditions, hepatotoxicity, and renal injury. Through its Clinical Laboratory Services segment, Enzo Biochem provides a spectrum of molecular and other clinical laboratory tests and procedures. These are utilized in routine patient care by medical professionals to aid in establishing or corroborating diagnoses, monitoring treatment efficacy or medication levels, and uncovering previously undiagnosed conditions. This segment operates a full-scale clinical laboratory in Farmingdale, New York, supported by a network of 30 patient service centers throughout New York and New Jersey. Furthermore, it manages specialized "STAT" or rapid response laboratories in New York City and Connecticut, along with a complete phlebotomy center and an internal logistics department. The Therapeutics segment is committed to devising innovative solutions for gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem promotes its products and services globally through a dedicated direct sales force and an established network of distributors. The company was founded in 1976 and maintains its corporate headquarters in New York, New York.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open ENZB position with:
Real after-tax yield depends on where you live and how you hold ENZB.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 14.31% | 11.51% | $1,431 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 12.16% | 9.36% | $1,216 / yr |
| πΊπΈ US Taxable (20%) | 20% | 11.45% | 8.65% | $1,145 / yr |
| π¬π§ UK ISA | 0% | 14.31% | 11.51% | $1,431 / yr |
| π¬π§ UK Taxable | 8.75% | 13.06% | 10.26% | $1,306 / yr |
| π¨π¦ TFSA | 0% | 14.31% | 11.51% | $1,431 / yr |
| π¨π¦ CA Taxable | 25% | 10.73% | 7.93% | $1,073 / yr |
| π¦πΊ Super (pension) | 15% | 12.16% | 9.36% | $1,216 / yr |
| π¦πΊ AU Taxable | 30% | 10.02% | 7.22% | $1,002 / yr |
| π©πͺ DE Taxable | 26.375% | 10.54% | 7.74% | $1,054 / yr |
| π«π· FR Taxable | 30% | 10.02% | 7.22% | $1,002 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.10/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
ENZB pays quarterly β 4 times per year. Next ex-div: TBD.
How ENZB compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ENZB sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2025-08-20 | 430,000 | $0.01 | $4.3K | ||
| D-Return | 2025-08-20 | 239,992 | $0.01 | $2.4K | ||
| D-Return | 2025-08-20 | 25,000 | β | β | ||
| D-Return | 2025-08-20 | 28,328 | $0.01 | $283.00 | ||
| D-Return | 2025-08-20 | 277,237 | $0.01 | $2.8K | ||
| D-Return | 2025-08-20 | 55,400 | β | β | ||
| D-Return | 2025-08-20 | 45,065 | $0.01 | $451.00 | ||
| A-Award | 2025-01-16 | 142,897 | β | β | ||
| A-Award | 2025-01-16 | 142,897 | β | β | ||
| A-Award | 2025-01-16 | 142,897 | β | β |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ENZB dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Enzo Biochem, Inc. (ENZB) is currently trading at $0.70, 81% below its 52-week high. The current dividend yield is 14.31% based on an annual payout of $0.10 per share.
Enzo Biochem, Inc. (ENZB) is a healthcare stock currently trading at $0.70 with a dividend yield of 14.31%. The company pays an annual dividend of $0.10 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only β not financial advice.
Real users. No sign-up required to leave a review.
βFinally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.β
βI've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly β $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.β
βReally solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.β
βAs someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.β
βThe Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.β
Reviews reflect users' personal experiences. Not financial advice.
Leave a review βIf DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever